Breaking News

Alvogen Appoints Americas Head

October 31, 2013

Alkins brings 25 years of commercial experience

Darren Alkins has been appointed president of Alvogen Americas and will become a member of the executive board. Mr. Alkins will be leading Alvogen’s sales, marketing and business development efforts in North and South America. He will also be responsible for Alvogen’s third party business units in the U.S., including Norwich Pharma Services, a contract manufacturing and clinical research organization based in Norwich, NY.
 
Mr. Alkins brings 25 years of commercial experience in brand and generic sales and marketing, as well as third party business development. Most recently, he led the business development and alliance management team for Teva Pharmaceuticals, driving key initiatives developing new and existing business for the company in the U.S. He also served as senior vice president of corporate development at Stiefel Laboratories and president of Glades Pharmaceuticals. He began his career at Bristol-Myers Squibb, and was promoted through various sales, marketing, operations and business development functions.
 
“I am delighted to welcome Darren to the executive board, a role for which he is well prepared through his extensive industry experience. With more than 25 years of commercial experience in both branded and generic pharmaceuticals, Darren’s successful history driving key organizational initiatives, expertise and leadership will help lead Alvogen into our next phase of growth,” said Robert Wessman, chairman and chief executive officer of Alvogen.

blog comments powered by Disqus
  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016